Applied Therapeutics, Inc.
Applied Therapeutics is a biopharmaceutical company dedicated to creating transformative treatments to address high unmet need rare diseases. The company leverages technological advances and focused development strategies to rapidly bring new treatments to market for patients with high unmet medical needs, especially in rare diseases.
Industries
Nr. of Employees
small (1-50)
Applied Therapeutics, Inc.
545 Fifth Avenue, Suite 1400, New York, NY 10017
Patents
Products
Clinical-stage aldose reductase inhibitor candidate — galactosemia
Small-molecule aldose reductase inhibitor candidate in development for treatment of galactosemia; has received pediatric rare disease and orphan designations.
Clinical-stage aldose reductase inhibitor candidate — SORD deficiency
Clinical development program evaluating an aldose reductase inhibitor to reduce toxic sorbitol levels and improve symptoms in patients with SORD deficiency; includes the INSPIRE registrational trial and home-based genetic screening for enrollment.
Clinical-stage small-molecule candidate — diabetic cardiomyopathy
Small-molecule therapeutic candidate in development for diabetic cardiomyopathy, advanced into Phase 3 registrational study activity.
Clinical-stage aldose reductase inhibitor candidate — galactosemia
Small-molecule aldose reductase inhibitor candidate in development for treatment of galactosemia; has received pediatric rare disease and orphan designations.
Clinical-stage aldose reductase inhibitor candidate — SORD deficiency
Clinical development program evaluating an aldose reductase inhibitor to reduce toxic sorbitol levels and improve symptoms in patients with SORD deficiency; includes the INSPIRE registrational trial and home-based genetic screening for enrollment.
Clinical-stage small-molecule candidate — diabetic cardiomyopathy
Small-molecule therapeutic candidate in development for diabetic cardiomyopathy, advanced into Phase 3 registrational study activity.
Expertise Areas
- Rare disease drug development
- Aldose reductase inhibitor therapeutics
- Clinical trial management (Phase 1–3)
- Biomarker-driven endpoint development
Key Technologies
- Aldose reductase inhibitor small-molecule therapeutics
- Biochemical biomarker assays (sorbitol quantification)
- MRI-based imaging endpoints
- Decentralized sample collection (home blood draws)
News & Updates
Presentation of full 12-month clinical results and new topline data from the INSPIRE Phase 2/3 trial of Govorestat in CMT-SORD at the Peripheral Nerve Society 2025 Annual Meeting.
Report on financial results for the first quarter of 2025, including clinical data from the INSPIRE trial.
Announcement of acceptance of late-breaking abstract for oral presentation, including full 12-month clinical data from the INSPIRE Phase 3 trial.
Financial results for Q4 and full year 2024, including leadership appointments.
Filing of Form 12b-25 to notify of delay in filing annual report.
Appointment of Todd Baumgartner as Chief Regulatory Officer to advance regulatory preparations.
Presentation of full 12-month clinical results and new topline data from the INSPIRE Phase 2/3 trial of Govorestat in CMT-SORD at the Peripheral Nerve Society 2025 Annual Meeting.
Report on financial results for the first quarter of 2025, including clinical data from the INSPIRE trial.
Announcement of acceptance of late-breaking abstract for oral presentation, including full 12-month clinical data from the INSPIRE Phase 3 trial.
Financial results for Q4 and full year 2024, including leadership appointments.
Filing of Form 12b-25 to notify of delay in filing annual report.
Appointment of Todd Baumgartner as Chief Regulatory Officer to advance regulatory preparations.